State Street’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-2,882,645
| Closed | -$1.01M | – | 3744 |
|
|
2016
Q3 | $1.01M | Buy |
2,882,645
+128,675
| +5% | +$45.2K | ﹤0.01% | 3191 |
|
|
2016
Q2 | $1.28M | Buy |
2,753,970
+352,324
| +15% | +$164K | ﹤0.01% | 3195 |
|
|
2016
Q1 | $3.27M | Buy |
2,401,646
+40,524
| +2% | +$55.1K | ﹤0.01% | 2778 |
|
|
2015
Q4 | $3.47M | Buy |
2,361,122
+199,243
| +9% | +$293K | ﹤0.01% | 2738 |
|
|
2015
Q3 | $3.42M | Buy |
2,161,879
+124,107
| +6% | +$196K | ﹤0.01% | 2723 |
|
|
2015
Q2 | $3.47M | Buy |
2,037,772
+263,724
| +15% | +$449K | ﹤0.01% | 2830 |
|
|
2015
Q1 | $2.47M | Buy |
1,774,048
+1,231
| +0.1% | +$1.71K | ﹤0.01% | 2945 |
|
|
2014
Q4 | $2.68M | Buy |
1,772,817
+46,252
| +3% | +$69.8K | ﹤0.01% | 2910 |
|
|
2014
Q3 | $3.56M | Buy |
1,726,565
+83,482
| +5% | +$172K | ﹤0.01% | 2723 |
|
|
2014
Q2 | $5.03M | Sell |
1,643,083
-5,560,762
| -77% | -$17M | ﹤0.01% | 2587 |
|
|
2014
Q1 | $18M | Buy |
7,203,845
+2,191,609
| +44% | +$5.48M | ﹤0.01% | 1864 |
|
|
2013
Q4 | $24.9M | Buy |
5,012,236
+4,121,977
| +463% | +$20.4M | ﹤0.01% | 1593 |
|
|
2013
Q3 | $2.02M | Buy |
890,259
+51,025
| +6% | +$116K | ﹤0.01% | 3034 |
|
|
2013
Q2 | $1.86M | Buy |
+839,234
| New | +$1.86M | ﹤0.01% | 3010 |
|
State Street's RXII Position: Q4 2016 in Review
State Street sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 2,882,645 shares — an estimated $1.01M sold.
State Street first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $24.9M in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- State Street reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- State Street sold 2,882,645 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $1.01M.
- State Street first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- State Street's GALENA BIOPHARMA INC COM position peaked at $24.9M in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on State Street's 13F filing for Q4 2016, filed 9 Feb 2017.